Farletuzumab: Phase II started

Eisai’s Morphotek Inc. subsidiary began the double-blind, placebo-controlled, international Phase II 003-011 trial to evaluate 5 mg/kg IV farletuzumab weekly in combination with carboplatin and eithe...